Genetically Encoded Green Fluorescent Biosensors for Monitoring UDP-GlcNAc in Live Cells

Zefan Li, Jing Zhang, and Hui-wang Ai

ABSTRACT: Uridine diphosphate N-acetylg glucosamine (UDP-GlcNAc) is a nucleotide sugar used by glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is thus a central metabolite connecting nutrition, metabolism, signaling, and disease. There is a great interest in monitoring UDP-GlcNAc in biological systems. Here, we present the first genetically encoded, green fluorescent UDP-GlcNAc sensor (UGAcS), an optimized insertion of a circularly permuted green fluorescent protein (cpGFP) into an inactive mutant of an Escherichia coli UDP-GlcNAc transferase, for ratiometric monitoring of UDP-GlcNAc dynamics in live mammalian cells. Although UGAcS responds to UDP-GlcNAc quite selectively among various nucleotide sugars, UDP and uridine triphosphate (UTP) interfere with the response. We thus developed another biosensor named UXPS, which is responsive to UDP and UTP but not UDP-GlcNAc. We demonstrated the use of the biosensors to follow UDP-GlcNAc levels in cultured mammalian cells perturbed with nutritional changes, pharmacological inhibition, and knockdown or overexpression of key enzymes in the UDP-GlcNAc synthesis pathway. We further utilized the biosensors to monitor UDP-GlcNAc concentrations in pancreatic MIN6 β-cells under various culture conditions.

INTRODUCTION

Uridine diphosphate N-acetylg glucosamine (UDP-GlcNAc), the major end-product of the hexosamine biosynthetic pathway (HBP), is one of the most important nucleotide sugars in living organisms. The HBP branches out from glycolysis and consumes ∼0.006–3% of total glucose, along with glutamine, acetyl-coenzyme A (Ac-CoA), adenosine triphosphate (ATP), and uridine triphosphate (UTP). Because multiple types of metabolic molecules, including carbohydrates, amino acids, fatty acids, and nucleotides, regulate the flux of HBP, UDP-GlcNAc has been considered an integrator of nutritional and metabolic signals.

As an activated N-acetylg glucosamine (GlcNAc) donor, UDP-GlcNAc is vital for the glycosytransferase-catalyzed formation of various glycosaminoglycans, glycoproteins, glycolipids, and glycoRNA. In mammalian cells, glycosylation primarily occurs in the endoplasmic reticulum (ER) and Golgi. The glycosylated products are typically translocated to the extracellular space, playing critical roles such as maintaining structural stability, modulating cell–matrix or cell–cell interaction, regulating cell proliferation and migration, and initiating other types of signaling. Moreover, UDP-GlcNAc is an essential substrate for O-GlcNAcylation, a reversible post-translational modification of nucleocytoplasmic proteins. O-GlcNAc transferase (OGT) catalyzes the transfer of the GlcNAc subunit from UDP-GlcNAc to the serine or threonine residues of proteins, while O-GlcNAcase (OGA) hydrolyzes the modification to generate free proteins and GlcNAc. This dynamic and tightly regulated process, analogous to more well-known phosphorylation, is involved in a large array of intracellular signaling processes.

Aberrant O-GlcNAcylation has been linked to aging, neurodegeneration, cancer, cardiovascular diseases, and metabolic disorders. The concentration of UDP-GlcNAc is one of the several key factors regulating glycosylation. The drastic increase of the β1,6-branched oligosaccharide levels was observed in B16 melanoma cells incubated with GlcNAc. In another example, deleterious mutations in SLC35A3, the major Golgi UDP-GlcNAc transporter, were identified in patients with autism spectrum disorder, arthrogryposis, and epilepsy. These mutations reduce UDP-GlcNAc transport into the ER, leading to a massive decrease of highly branched N-glycans and a drastic increase of lower branched glycoforms at the cell surface. The UDP-GlcNAc level has also been found to regulate intracellular O-GlcNAcylation. In vitro character-
UDP-GlcNAc-bound forms have been reported. We selected murG as the sensory domain to build a UDP-GlcNAc biosensor, UXPS, which is only responsive to UDP and UTP. Because UDP and UTP interfere with the response of UXPS at high concentrations, we performed directed evolution to optimize the biosensor. We demonstrated the use of the biosensors to follow UDP-GlcNAc levels, but these methods require cell lysis and provide little spatiotemporal resolution. To address this technical gap, we engineered the biosensors in mammalian cells, and murG is unlikely to be present in the bacterial cell membrane. MurG has a high binding affinity to UDP-GlcNAc (~1.4 μM), and its structures in the apo and UDP-GlcNAc-bound forms have been reported.

We selected murG as the sensory domain to build a UDP-GlcNAc sensor. By carefully examining the structures of murG, we identified that the binding of UDP-GlcNAc triggers a structural conversion of residues 60–70 in murG from a loop into an α-helix (Supporting Information, Figure S1). We further confirmed the significant conformation change at this loop by analyzing the changes of dihedral angles of every four consecutive Cα atoms (Figure S2).

We next inserted cpGFP to the above-identified loop between residues 64 and 65 of murG (Figure 1A and Figure S3). A fully randomized residue was introduced to each of the two junctions as the linkers. We screened the library and identified a UGAcS0.1 mutant with a 30% response ((R − R0)/R0 or ΔR/ΔR0, where R is the ratio of fluorescence with 488 nm excitation to that with 400 nm excitation) to UDP-GlcNAc. To increase the sensor’s response to UDP-GlcNAc, we performed three rounds of error-prone PCR, and the screening of these libraries resulted in UGAcS0.2 showing a 300% (ΔR/ΔR0) response.

Although our primary goal is to apply the fluorescent biosensors in mammalian cells, and murG is unlikely to be active in mammalian cells where its lipid-linked peptidoglycan substrate is not present, we still performed saturation mutagenesis on the catalytic His19 residue of murG in UGAcS0.2. This residue is essential for catalysis and conserved in murG from 73 orthologues. Our screening of the mutants led to an enzymatically inactive His19Ser mutant (UGAcS0.3) but is comparable to UGAcS0.2 in terms of the UDP-GlcNAc responsiveness.

Because UDP is a natural inhibitor and regulator of UDP-sugar transferases, we examined the fluorescence of UGAcS0.3 upon the addition of UDP. UGAcS0.3 showed a higher response to UDP than UDP-GlcNAc. Therefore, we next devoted our effort to engineering UGAcS0.3 for increased specificity to UDP-GlcNAc versus UDP. We chose five pairs of residues (residues 192 and 193, residues 16 and 127, residues 164 and 269, or residues 244 and 245) in the ligand-binding

![Image](115x650 to 215x730)

**Figure 1.** Design and in vitro characterization of the biosensors. (A) Illustration of the sensor design, showing the cpGFP insertion between residues 64 and 65 of the murG glycosyltransferase. Also highlighted is a UDP-GlcNAc molecule in the substrate-binding pocket. (B) Fluorescence excitation and emission spectra of UGAcS before and after addition of 1 mM UDP-GlcNAc. Responses of UGAcS (C) or UXPS (D), presented as normalized fluorescence excitation ratios (488 nm/400 nm), to 100 μM of various nucleoside sugars and other related cellular metabolites. Data are presented as mean ± SD (n = 3 technical repeats). Dose-dependent responses of UGAcS (E) or UXPS (F) to UDP or UDP-GlcNAc.

**RESULTS AND DISCUSSION**

Design, Engineering, and in Vitro Characterization of the UGAcS. MurG is a well-characterized E. coli UDP-GlcNAc transferase involved in synthesizing lipid-linked precursors to assemble peptidoglycan, the polymeric cell wall outside the bacterial cell membrane. MurG has a high binding affinity to UDP-GlcNAc (~1.4 μM), and its structures in the apo and UDP-GlcNAc-bound forms have been reported.

We selected murG as the sensory domain to build a UDP-GlcNAc biosensor. By carefully examining the structures of murG, we identified that the binding of UDP-GlcNAc triggers a structural conversion of residues 60–70 in murG from a loop into an α-helix (Supporting Information, Figure S1). We further confirmed the significant conformation change at this loop by analyzing the changes of dihedral angles of every four consecutive Cα atoms (Figure S2).

We next inserted cpGFP to the above-identified loop between residues 64 and 65 of murG (Figure 1A and Figure S3). A fully randomized residue was introduced to each of the two junctions as the linkers. We screened the library and identified a UGAcS0.1 mutant with a 30% response ((R − R0)/R0 or ΔR/ΔR0, where R is the ratio of fluorescence with 488 nm excitation to that with 400 nm excitation) to UDP-GlcNAc. To increase the sensor’s response to UDP-GlcNAc, we performed three rounds of error-prone PCR, and the screening of these libraries resulted in UGAcS0.2 showing a 300% (ΔR/ΔR0) response.

Although our primary goal is to apply the fluorescent biosensors in mammalian cells, and murG is unlikely to be active in mammalian cells where its lipid-linked peptidoglycan substrate is not present, we still performed saturation mutagenesis on the catalytic His19 residue of murG in UGAcS0.2. This residue is essential for catalysis and conserved in murG from 73 orthologues. Our screening of the mutants led to an enzymatically inactive His19Ser mutant (UGAcS0.3) but is comparable to UGAcS0.2 in terms of the UDP-GlcNAc responsiveness.

Because UDP is a natural inhibitor and regulator of UDP-sugar transferases, we examined the fluorescence of UGAcS0.3 upon the addition of UDP. UGAcS0.3 showed a higher response to UDP than UDP-GlcNAc. Therefore, we next devoted our effort to engineering UGAcS0.3 for increased specificity to UDP-GlcNAc versus UDP. We chose five pairs of residues (residues 192 and 193, residues 16 and 127, residues 164 and 269, or residues 244 and 245) in the ligand-binding
pocket and performed saturation mutagenesis. Screening of these libraries resulted in UGAcS0.4 with mutations at residues 192 and 193. In comparison with UGAcS0.3, UGAcS0.4 showed increased responsiveness to UDP-GlcNAc and reduced responsiveness to UDP. Despite the progress, we were unable to identify a mutant to exclude the UDP interference entirely.

From UGAcS0.4, we performed two more rounds of random mutagenesis. By screening these libraries for improved UDP-GlcNAc responsiveness, we arrived at UGAcS, which showed a nearly 700% response ($\Delta R/R_0$) to 1 mM UDP-GlcNAc (Figure 1B and Figure S4). We further tested the specificity of UGAcS using various nucleotide sugars and other related compounds at physiologically relevant concentrations (Figure 1C). UGAcS responded to UDP-GlcNAc, UDP, and UTP. Other tested nucleotide sugars, including uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) and uridine diphosphate glucose (UDP-Glc) that are structurally very close to UDP-GlcNAc, induced little fluorescence change.

After we realized that it might be unrealistic to engineer a fully specific UDP-GlcNAc biosensor from the glycosyltransferase, we sought to identify a UDP sensor, which could be used as a control to cross-check the responses of the UGAcS variants. From one of the ligand-binding-pocket mutagenesis libraries mentioned above, we identified a mutant (UXPS), which is responsive to UDP and UTP, not to UDP-GlcNAc and other nucleotide sugars (Figure 1D and Figure S4).

We next titrated UGAcS and UXPS with various concentrations of UDP-GlcNAc and UDP (Figure 1E,F). The apparent dissociation constant ($K_d$) values (deduced from the fluorescence responses of the sensors) for UGAcS were determined to be 72 ± 4 and 26 ± 1 μM in the presence of UDP-GlcNAc and UDP, respectively, while UXPS responded to UDP with an apparent $K_d$ of 6 ± 1 μM.

Monitoring of UDP-GlcNAc Changes in HEK 293T Cells. 2-Deoxy-d-glucose (2-DG) is a glucose analogue, and 2-deoxy-d-glucose-6-phosphate (2-DG6P) intracellularly formed from 2-DG competitively inhibits hexokinase (HK) and phosphoglucose isomerase (PGI), which are highlighted in magenta. Responses of UGAcS (B) or UXPS (C), given as normalized fluorescence excitation ratios (488 nm/400 nm), to 3 h of incubation with 10 mM 2-DG, or 3 h of 10 mM 2-DG incubation followed by washout and an addition 3 h culture in normal medium. (D) HILIC-MS analysis of relative UDP-HexNAc concentrations in extracts of HEK 293T cells untreated or treated with 10 mM 2-DG. (E) Representative mass spectrograms of the samples in panel D. The $m/z = 606$ peak represents the major isotope peak for UDP-HexNAc. A-C, with 13C-double-labeled UDP-GlcNAc ($^{13}$C$_2$-UDP-GlcNAc) doped into the cell extracts as an internal standard, contributing primarily to the $m/z = 608$ peak. Data in panels B–D are presented as mean ± SEM ($n = 3$ wells of cells for each group). P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test (***, $P < 0.001$; **, $P < 0.05$; and n.s., not significant, $P \geq 0.05$).

Figure 2. UDP-GlcNAc level changes in HEK 293T cells perturbed with 2-DG. (A) Schematic illustration of the hexosamine biosynthetic pathway (HBP) responsible for the production of UDP-GlcNAc. 2-DG (2-deoxy-d-glucose) is a glycolysis inhibitor acting on hexokinase (HK) and phosphoglucose isomerase (PGI), which are highlighted in magenta. Responses of UGAcS (B) or UXPS (C), given as normalized fluorescence excitation ratios (488 nm/400 nm), to 3 h of incubation with 10 mM 2-DG, or 3 h of 10 mM 2-DG incubation followed by washout and an addition 3 h culture in normal medium. (D) HILIC-MS analysis of relative UDP-HexNAc concentrations in extracts of HEK 293T cells untreated or treated with 10 mM 2-DG. (E) Representative mass spectrograms of the samples in panel D. The $m/z = 606$ peak represents the major isotope peak for UDP-HexNAc. 13C-double-labeled UDP-GlcNAc ($^{13}$C$_2$-UDP-GlcNAc) was doped into the cell extracts as an internal standard, contributing primarily to the $m/z = 608$ peak. Data in panels B–D are presented as mean ± SEM ($n = 3$ wells of cells for each group). P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test (***, $P < 0.001$; **, $P < 0.05$; and n.s., not significant, $P \geq 0.05$).

The glutamine fructose-6-phosphate aminotransferase (GFAT) is a feedback-regulated rate-limiting enzyme in the HBP. Since glucosamine (GlcN) enters the HBP downstream of GFAT (Figure 2A), GlcN is a potent stimulator of HBP and can rapidly increase the intracellular concentration of UDP-GlcNAc.24 We used a confocal microscope equipped with 488 and 405 nm lasers to follow GlcN-stimulated UDP-GlcNAc elevation in HEK 293T cells. Upon GlcN stimulation,
the fluorescence with 488 nm excitation increased along with the fluorescence decrease of UDP-GlcNAc with 405 nm excitation (Figure 3A,B), resulting in an overall ~70% ratiometric change ($\Delta R/R_0$). Most of the change was completed within the first 30 min poststimulation. In contrast, GlcN triggered an ~33% ratiometric change ($\Delta R/R_0$) of the UXPS fluorescence in the opposite direction (Figure 3C,D). The observed fluorescence change of UXPS is not surprising because the GlcN-dependent UDP-GlcNAc synthesis process may consume UTP quickly. Although the opposite responses of UGAcS and UXPS can exclude the possibility of the observed UGAcS response being caused by pH changes, we further introduced Arg164Ala and Glu269Ala double mutations into UXPS, resulting in a deactivated mutant (termed dUGAcS) unresponsive to UDP-GlcNAc, UTP, and UDP-phosphate (Figure S6). We tested dUGAcS-expressing HEK 293T cells against GlcN stimulation and observed no response (Figure 3E,F). Collectively, these results confirmed that GlcN indeed increased the intracellular UDP-GlcNAc concentration and that UGAcS successfully detected this relatively rapid increase of UDP-GlcNAc in HEK 293T cells.

We next utilized the biosensors to examine UDP-GlcNAc concentration changes in response to the genetic disruption of two key enzymes in the HBP. GFAT is the first and rate-limiting enzyme, while UDP-N-acetylglucosamine pyrophosphorylase (UAP) is the last enzyme in the pathway and is responsible for the direct synthesis of UDP-GlcNAc (Figure 4A). We used short hairpin RNAs (shRNAs) to knock down GFAT or UAP. Expression vectors coexpressing corresponding shRNAs and the GFAT1 or UAP1 gene were used for comparison and normalization. Responses of UGAcS (B) or UXPS (C), presented as normalized fluorescence excitation ratios (488 nm/400 nm) for UGAcS or UXPS (D), were analyzed for each group. P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; **P < 0.01; *P < 0.05; and n.s., not significant, P ≥ 0.05).

GFAT or UAP. The effectiveness of the shRNAs was first confirmed using fluorescence assays with HEK 293T cells coexpressing corresponding shRNAs and the GFAT1 or UAP1 gene fused to a red fluorescent protein (RFP) mScarlet-I via a P2A self-cleaving peptide, as well as reverse transcription-quantitative PCR (RT-qPCR) assays (Figure S7). The GFAT and UAP shRNA variants that induced the most significant decrease of mScarlet-I fluorescence and mRNA abundance were selected for further experiments. A scramble nontargeting shRNA sequence (shNC) was included as a negative control. Next, we used the shRNA lentiviral vectors to infect HEK 293T cells, to which the gene of UGAcS or UXPS was further introduced by transfection. As expected, GFAT or UAP knockdown decreased the UDP-GlcNAc level, as the fluorescence excitation ratios ($R_{488/400}$) of UGAcS were reduced compared to the shNC control group (Figure 4B). Meanwhile, the fluorescence excitation ratios ($R_{488/400}$) of UXPS in the experimental groups were slightly higher (statistically insignificant) than the shNC control group (Figure 4C). Furthermore, the same response trend was observed when GFAT was pharmacologically inhibited using DON (6-diazo-5-oxo-l-norleucine) (Figure S8).

We also examined the impact of overexpressing GFAT1 or UAP1 on the UDP-GlcNAc level. The sensor responses are

---

Figure 3. Glucosamine (GlcN)-induced UDP-GlcNAc increase in HEK 293T cells. Representative ratiometric images of HEK 293T cell expressing UGAcS (A), UXPS (C), or dUGAcS (E) with two excitation wavelengths (488 nm/405 nm) before and after treatment with 5 mM GlcN (scale bars, 40 μm). Quantitative traces of normalized fluorescence excitation ratios (488 nm/405 nm) for UGAcS (B), UXPS (D), or dUGAcS (F) in HEK 293T cells. Data are presented as mean ± SD (n = 10 cells from 3 replicating wells for each group).

Figure 4. UDP-GlcNAc level changes in response to knockdown or overexpression of GFAT or UAP in HEK 293T cells. (A) Schematic illustration of the HBP UDP-GlcNAc synthesis pathway. Highlighted in magenta are the two enzymes selected for genetic manipulation in this study. Responses of UGAcS (B) or UXPS (C), presented as normalized fluorescence excitation ratios (488 nm/400 nm), to shRNA knockdown of GFAT or UAP. A negative shRNA control, shNC, was used for comparison and normalization. Responses of UGAcS (D) or UXPS (E), given as normalized fluorescence excitation ratios (488 nm/400 nm), to the overexpression of P2A-mScarlet-I or GFAT1-P2A-mScarlet-I. The overexpression of mScarlet-I alone was used for comparison and normalization. Data in panels B–E are presented as mean ± SEM (n = 3 wells of cells for each group). P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; **P < 0.01; *P < 0.05; and n.s., not significant, P ≥ 0.05).
expressing cells increased by for dUGAcS-expressing cells (Figure S9A,B). The results expressing cells (Figure 5CD), and no response was observed ∼ In contrast, an in high (25 mM), low (2 mM), or no glucose DMEM (scale bars, 40 μm). Representative ratiometric images of MIN6 cells expressing UGAcS (E) or UXPS (G) with two excitation wavelengths (488 nm/405 nm) cultured Data in panels B, D, F, and H are presented as mean ± SEM (n = 12 cells from 3 replicating wells for each group). P values in panels B and D were determined by an unpaired two-tailed t-test (**P < 0.01). P values in panels F and H were determined by one-way ANOVA with Tukey’s multiple comparisons test (** ** P < 0.001; * P < 0.01; and n.s., not significant, P ≥ 0.05).

opposite to those in the knockdown experiments: GFAT1 or UAP1 overexpression increased the fluorescence excitation ratios (R_{488/400}) of UGAcS and decreased the fluorescence excitation ratios (R_{488/400}) of UXPS (Figure 4D,E). Moreover, in both the knockdown and overexpression experiments, manipulating the GFAT1 expression level induced more dramatic fluorescence responses than manipulating UAP1. This is again expected because GFAT plays the rate-limiting role in the HBP.

Imaging of UDP-GlcNAc Levels in Pancreatic MIN6 β-Cells. Pancreatic β-cells are responsible for synthesis and secretion of insulin, a key endocrine regulator of glucose levels in the blood and other tissues. The glucose metabolism of pancreatic β-cells is tightly coupled to insulin synthesis and secretion. Meanwhile, O-GlcNAc levels in β-cells have been linked to the regulation of insulin gene expression, proinsulin-to-insulin processing, and glucose-stimulated insulin secretion. In this context, we used our new biosensors to examine UDP-GlcNAc levels in MIN6 β-cells, a mouse insulinoma cell line, in response to various nutritional conditions. Expression of the biosensors in MIN6 cells resulted in bright green fluorescence. Upon 5 mM GlcN stimulation, the fluorescence excitation ratios (R_{488/400}) of UGAcS-expressing cells increased by ∼30% (Figure 5A,B) within 1 h. In contrast, an ∼25% decrease was observed for UXPS-expressing cells (Figure 5C,D), and no response was observed for dUGAcS-expressing cells (Figure S9A,B). The results suggest that GlcN, which bypasses the rate-limiting GFAT in the HBP, can stimulate the biosynthesis of UDP-GlcNAc in MIN6 cells in a manner similar to that in HEK 293T cells.

Next, MIN6 cells expressing these biosensors were subjected to glucose deprivation (replacing 25 mM glucose medium with 2 mM or no glucose medium) and imaged 20 h later. The fluorescence excitation ratio (R_{488/400}) of UGAcS under the no glucose condition was ∼50% lower than that under the 25 mM glucose condition, while we only observed a quite minimal decrease (statistically insignificant) of the fluorescence excitation ratio (R_{488/400}) of UXPS from the 25 mM to the 2 mM glucose condition (Figure 5E,F). The fluorescence changes of UXPS (Figure 5G,H) or dUGAcS (Figure S9C,D) were not significant under all conditions. We further examined the time course of UGAcS fluorescence changes in MIN6 cells from 25 to 0 mM glucose and found that 10 h of glucose deprivation was adequate to complete all fluorescence changes (Figure S10). Taken together, the UDP-GlcNAc level in MIN6 cells was sensitive to severe hypoglycemia but relatively insensitive to glucose concentration changes from 25 to 2 mM within the examined time frame. These findings corroborate a recent study on the mouse heart tissue with 5.5 and 25 mM glucose, which concluded that glucose availability alone does not regulate the HBP flux. In other studies, UDP-GlcNAc has been shown to directly inhibit GFAT via a negative feedback mechanism. The tight regulation of the HBP, however, does not necessarily

![Figure 5. Imaging of UDP-GlcNAc levels in pancreatic MIN6 β-cells. Representative ratiometric images of a MIN6 cell expressing UGAcS (A) or UXPS (C) with two excitation wavelengths (488 nm/405 nm) before and after a 1 h treatment with 5 mM GlcN (scale bars, 40 μm). Responses of UGAcS (B) or UXPS (D), given as normalized fluorescence excitation ratios (488 nm/405 nm), to 1 h of incubation with 5 mM GlcN. Representative ratiometric images of MIN6 cells expressing UGAcS (E) or UXPS (G) with two excitation wavelengths (488 nm/405 nm) cultured in high (25 mM), low (2 mM), or no glucose DMEM (scale bars, 40 μm). Responses of UGAcS (F) or UXPS (H), given as normalized fluorescence excitation ratios (488 nm/405 nm), after replacing high glucose (25 mM) medium with low (2 mM) or no glucose medium for 20 h. Data in panels B, D, F, and H are presented as mean ± SEM (n = 12 cells from 3 replicating wells for each group). P values in panels B and D were determined by an unpaired two-tailed t-test (**P < 0.01). P values in panels F and H were determined by one-way ANOVA with Tukey’s multiple comparisons test (** ** P < 0.001; * P < 0.01; and n.s., not significant, P ≥ 0.05).](image1)
undermine the importance of UDP-GlcNAc in nutritional signaling. First, multiple types of metabolic molecules are funneled into the HBP, and a collection of these molecules may be needed to drastically shift the HBP flux. In addition, the GFAT expression level and activity are highly responsive to other signals, and the HBP is thus likely regulated to different extents in diverse tissue types and under various pathophysiological conditions.39–41

## CONCLUSION

We have engineered a genetically encoded UDP-GlcNAc sensor (UGAcS) by inserting cpGFP into an inactivated UDP-GlcNAc transferase. Because UGAcS is also responsive to UDP and UTP, we further engineered a control sensor, UXPS, which is only responsive to UDP and UTP but not UDP-GlcNAc. We successfully applied the biosensors to monitoring UDP-GlcNAc level changes in HEK 293T cells in response to 2-DG-induced glycolysis inhibition, glucosamine stimulation, DON-induced GFAT inhibition, and the genetic manipulation of two key enzymes (GFAT and UAP) in the HBP. Finally, we used our biosensors to monitor UDP-GlcNAc levels in pancreatic MIN6 β-cells under various cell culture conditions. Our results suggest that glucose metabolism via the HBP is tightly regulated across a large glucose concentration range. Further research is clearly needed to further understand the regulatory mechanism of the HBP flux, and the fluorescent biosensors described here should facilitate these studies.

In addition to being used as research tools in studying the crucial roles of UDP-GlcNAc in disease and normal conditions, the biosensors may have translational applications. Modulation of the HBP has been considered as a promising method to treat diseases, such as cancer and diabetes.42,43 We envision the use of the biosensors to screen for chemical or genetic modulators of the HBP. In addition, murG is a key enzyme for peptidoglycan synthesis in bacteria,44 so these murG-based biosensors may be used to discover novel murG inhibitors as a new class of antibiotics.

Our effort to develop the first genetically encoded nucleotide sugar sensor will spur the development of future biosensors. UDP and UTP interfere with the response of UGAcS. Although UXPS can be used for cross-checking, a subset of treatment conditions may move the UGAcS. Although UXPS can be used for cross-checking, a biosensors. UDP and UTP interfere with the response of nucleotide sugar sensor will spur the development of future logical conditions.39

## ACKNOWLEDGMENTS

Research reported in this publication was supported by the NIH Common Fund Glycoscience Program and the National Cancer Institute of the National Institutes of Health under Award U01CA230817. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. pMD2.G (Addgene Plasmid 12259) and psPAX2 (Addgene Plasmid 12260) were gifts from Didier Trono (EPFL). pLKO.1 (Addgene Plasmid 172135, 172136, 172137, and 172138).

## REFERENCES

(1) Bond, M. R.; Hanover, J. A. A little sugar goes a long way: the cell biology of O-GlcNAc. J. Cell Biol. 2015, 208 (7), 869.
(2) Yang, X.; Qian, K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat. Rev. Mol. Cell Biol. 2017, 18 (7), 452.

(3) Olson, A. K.; Bouchard, B.; Zhu, W. Z.; Chatham, J. C.; Des Rosiers, C. First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in ex vivo mouse heart. J. Biol. Chem. 2020, 295 (7), 2018.

(4) Marshall, S.; Bacote, V.; Traxinger, R. R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 1991, 266 (8), 4706.

(5) Ong, Q.; Han, W.; Yang, X. O-GlcNAc as an Integrator of Signaling Pathways. Front. Endocrinol. (Lausanne, Switz.) 2018, 9, 599.

(6) Akella, N. M.; Ciraku, L.; Regnato, M. J. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019, 17 (1), 52.

(7) Flynn, R. A.; Pedram, K.; Malaker, S. A.; Batista, P. J.; Smith, B. A. H.; Johnson, A. G.; George, B. M.; Majzoub, K.; Villalta, P. W.; Carette, J. E.; et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell 2021, 184 (12), 3109.

(8) Hanover, J. A. Epigenetics gets sweeter: O-GlcNAc and the "histone code". Chem. Biol. 2010, 17 (12), 1272.

(9) Ramirez, D. H.; Aonbangkhen, C.; Wu, H. Y.; Naftaly, J. A.; Tang, S.; O'Meara, T. R.; Woo, C. M. Engineering a Proximity-Directed O-GlcNAc Transferase for Selective Protein O-GlcNAcylation in Cells. ACS Chem. Biol. 2020, 15 (4), 1059.

(10) Hao, Y.; Fan, X.; Shi, Y.; Zhang, C.; Sun, D. E.; Qin, K.; Qin, W.; Zhou, W.; Chen, X. Next-generation unnatural monosaccharides reveal that O-GlcNAc regulates plasminogen activating protein in the membrane. ACS Chem. Biol. 2021, 1769, 10 (1), 4065.

(11) Qin, W.; Lv, P.; Fan, X.; Quan, B.; Zhu, Y.; Qin, K.; Chen, Y.; Wang, C.; Chen, X. Quantitative time-resolved chemoproteomics reveals that stable O-GlcNAc regulates the BDNF downstream signaling pathway. Brain Res. Bull. 2017, 133, 80.

(12) Baumann, D.; Wong, A.; Akhphong, B.; Jo, S.; Pritchard, S.; Mohan, R.; Chung, G.; Zhang, Y.; Alejandro, E. U. Role of nutrient-driven O-GlcNAc-potranslational modification in pancreatic exocrine and endocrine islet development. Development 2020, 147 (7), dev156643.

(13) Ma, J.; Hart, G. W. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev. Proteomics 2013, 10 (4), 365.

(14) Todeschini, A. R.; Dias, W. B. Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression. Anal. Biochem. 2014, 448, 14.

(15) Nakajima, K.; Kitazume, S.; Angata, T.; Fujinawa, R.; Ohtsubo, K.; Miyoshi, J.; Taniguchi, N. Simultaneous determination of nucleotide sugars with ion-pair reversed-phase HPLC. Glycobiology 2010, 20 (7), 865.

(16) Crouvoisier, M.; Auger, G.; Blanot, D.; Mengin-Lecreulx, D. Role of the amino acid variants in the active site of MurG as evaluated by site-directed mutagenesis. Biochimie 2007, 89 (12), 1498.

(17) Hu, Y.; Chen, L.; Ha, S.; Gross, B.; Falcone, B.; Walker, D.; Mokhtarzadeh, M.; Walker, C. Crystal structure of the MurG-UDP-GlcNAc complex reveals common structural principles of a superfamily of glycosyltransferases. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (3), 845.

(18) Qin, W.; Lv, P.; Fan, X.; Quan, B.; Zhu, Y.; Qin, K.; Chen, Y.; Wang, C.; Chen, X. Quantitative time-resolved chemoproteomics reveals that stable O-GlcNAc regulates box C/D snoRNP biogenesis. Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (33), E6749.

(19) Pekkurnaz, G.; Trinidad, J. C.; Wang, X.; Kong, D.; Schwarz, T. L. Glucose regulates mitochondrial motility via Miton modification by O-GlcNAc transferase. Cell 2014, 158 (1), 54.

(20) Wani, W. Y.; Chatham, J. C.; Darley-Usmar, V.; McMahon, L. L.; Zhang, J. O-GlcNAcylation and neurodegeneration. Brain Res. Bull. 2017, 133, 80.

(21) Baumann, D.; Tong, A.; Akhphong, B.; Jo, S.; Pritchard, S.; Mohan, R.; Chung, G.; Zhang, Y.; Alejandro, E. U. Role of nutrient-driven O-GlcNAc-potranslational modification in pancreatic exocrine and endocrine islet development. Development 2020, 147 (7), dev156643.

(22) Ma, J.; Hart, G. W. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev. Proteomics 2013, 10 (4), 365.

(23) Todeschini, A. R.; Dias, W. B. Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression. Anal. Biochem. 2014, 448, 14.

(24) Qin, W.; Lv, P.; Fan, X.; Quan, B.; Zhu, Y.; Qin, K.; Chen, Y.; Wang, C.; Chen, X. Quantitative time-resolved chemoproteomics reveals that stable O-GlcNAc regulates box C/D snoRNP biogenesis. Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (33), E6749.

(25) Pekkurnaz, G.; Trinidad, J. C.; Wang, X.; Kong, D.; Schwarz, T. L. Glucose regulates mitochondrial motility via Miton modification by O-GlcNAc transferase. Cell 2014, 158 (1), 54.

(26) Wani, W. Y.; Chatham, J. C.; Darley-Usmar, V.; McMahon, L. L.; Zhang, J. O-GlcNAcylation and neurodegeneration. Brain Res. Bull. 2017, 133, 80.

(27) Baumann, D.; Wong, A.; Akhphong, B.; Jo, S.; Pritchard, S.; Mohan, R.; Chung, G.; Zhang, Y.; Alejandro, E. U. Role of nutrient-driven O-GlcNAc-potranslational modification in pancreatic exocrine and endocrine islet development. Development 2020, 147 (7), dev156643.

(28) Qin, W.; Lv, P.; Fan, X.; Quan, B.; Zhu, Y.; Qin, K.; Chen, Y.; Wang, C.; Chen, X. Quantitative time-resolved chemoproteomics reveals that stable O-GlcNAc regulates box C/D snoRNP biogenesis. Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (33), E6749.

(29) Pekkurnaz, G.; Trinidad, J. C.; Wang, X.; Kong, D.; Schwarz, T. L. Glucose regulates mitochondrial motility via Miton modification by O-GlcNAc transferase. Cell 2014, 158 (1), 54.

(30) Wani, W. Y.; Chatham, J. C.; Darley-Usmar, V.; McMahon, L. L.; Zhang, J. O-GlcNAcylation and neurodegeneration. Brain Res. Bull. 2017, 133, 80.

(31) Baumann, D.; Wong, A.; Akhphong, B.; Jo, S.; Pritchard, S.; Mohan, R.; Chung, G.; Zhang, Y.; Alejandro, E. U. Role of nutrient-driven O-GlcNAc-potranslational modification in pancreatic exocrine and endocrine islet development. Development 2020, 147 (7), dev156643.
Lauzier, B.; et al. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat. Commun. 2018, 9 (1), 374.

(40) Li, L.; Shao, M.; Peng, P.; Yang, C.; Song, S.; Duan, F.; Jia, D.; Zhang, M.; Zhao, J.; Zhao, R.; et al. High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 2017, 8 (12), 19205.

(41) Ruegenberg, S.; Mayr, F.; Atanassov, I.; Baumann, U.; Denzel, M. S. Protein kinase A controls the hexosamine pathway by tuning the feedback inhibition of GFAT-1. Nat. Commun. 2021, 12 (1), 2176.

(42) Walter, L. A.; Lin, Y. H.; Halbrook, C. J.; Chuh, K. N.; He, L.; Pedowitz, N. J.; Batt, A. R.; Brennan, C. K.; Stiles, B. L.; Lyssiotis, C. A.; et al. Inhibiting the Hexosamine Biosynthetic Pathway Lowers O-GlcNAcylation Levels and Sensitizes Cancer to Environmental Stress. Biochemistry 2020, 59 (34), 3169.

(43) Buse, M. G. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am. J. Physiol. Endocrinol. Metab. 2006, 290 (1), E1.

(44) Hu, Y.; Helm, J. S.; Chen, L.; Ginsberg, C.; Gross, B.; Kraybill, B.; Tiyanont, K.; Fang, X.; Wu, T.; Walker, S. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem. Biol. 2004, 11 (5), 703.

(45) Anderson, C. M.; Parkinson, F. E. Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides. Trends Pharmacol. Sci. 1997, 18 (10), 387.

(46) Huang, Z.; Xie, N.; Illes, P.; Di Virgilio, F.; Ulrich, H.; Semenov, A.; Verkhratsky, A.; Sperlagh, B.; Yu, S. G.; Huang, C.; et al. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct. Target Ther. 2021, 6 (1), 162.

(47) Elliott, M. R.; Ravichandran, K. S. The Dynamics of Apoptotic Cell Clearance. Dev. Cell 2016, 38 (2), 147.

(48) Chen, X.; Jou, M. J.; Yoon, J. An "Off-On" type UTP/UDP selective fluorescent probe and its application to monitor glycosylation process. Org. Lett. 2009, 11 (10), 2181.

(49) Kambam, S.; Ren, X.; Zheng, C.; Wang, F.; Wang, Y.; Chen, H.; Yin, J.; Xie, J.; Chen, X. The synthesis of UDP-selective fluorescent probe and its imaging application in living cells. Bioorg. Med. Chem. Lett. 2015, 25 (2), 262.

(50) Lv, X. W.; Wang, G. K.; Zou, X. J.; Xie, X. G.; Zhou, Y. Study of a 1,8-naphthylamide derivative as uridine diphosphate selective probe: Synthesis, optical properties and in vivo imaging application. Dyes Pigm. 2017, 142, 552.